Effect of Degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade study
Articolo
Data di Pubblicazione:
2022
Abstract:
To characterize the changes in bone mineral density (BMD) and bone turnover markers after degarelix administration in prostate cancer patients without bone metastases. To explore the predictive role of body composition on treatment induced bone loss.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
ALMI; BMD; bone health; degarelix; prostate cancer
Elenco autori:
Palumbo, Carlotta; Dalla Volta, Alberto; Zamboni, Stefania; Mazziotti, Gherardo; Zamparini, Manuel; Triggiani, Luca; Borghetti, Paolo; Maffezzoni, Filippo; Bresciani, Roberto; Rinaudo, Luca; Valcamonico, Francesca; Farina, Davide; Magrini, Stefano Maria; Antonelli, Alessandro; Simeone, Claudio; Berruti, Alfredo
Link alla scheda completa:
Pubblicato in: